43 completed, 6 terminated, 2 not yet recruiting, 2 unknown. 55 Phase 2, 5 Phase 1, 5 Phase 3.
Follow Dyslipidemia: new trials by email Literature Review of Dyslipidemia trials Research Report on Dyslipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Synbiotic as an Adjuvant Therapy for Dyslipidaemia and Gut Health Synbiotic (LAB12 and SWEOAT® Bran), Oat-based Placebo - Dyslipidemia | Phase 2 | Not yet recruiting | Universiti Teknologi Mara | 190 | 2026-12-02 | 2026-11-05 |
| Study of the Safety and Efficacy of Prenofitol Tablets 1 tablet of Prenofitol, 2 tablets of Prenofitol, 1 tablet of placebo - Dyslipidemia | Phase 2 | Not yet recruiting | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 160 | 2026-11-02 | 2026-11-02 |
| Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet Atorvastatin 10mg, Modification of dietary fat composition - Epilepsy, Dyslipidemia | Phase 1 / Phase 2 | Enrolling by invitation | Johns Hopkins University | 22 | 2024-10-04 | 2026-10-19 |
| A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia AZD0780, Placebo - Dyslipidemia | Phase 2 | Completed | AstraZeneca | 428 | 2024-01-19 | 2025-11-17 |
| A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. Obicetrapib, Placebo - Dyslipidemia, Hypercholesterolemia | Phase 2 | Completed | NewAmsterdam Pharma | 102 | 2022-06-27 | 2024-10-29 |
| A Study of AZD8233 in Participants With Dyslipidemia. Part A:Placebo, Part A:AZD8233, Part B:Placebo - Dyslipidemia | Phase 1 / Phase 2 | Completed | AstraZeneca | 87 | 2021-01-20 | 2024-12-24 |
| Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR K-877-ER (Dose A), K-877-ER (Dose B), K-877-IR - Dyslipidemia | Phase 2 | Completed | Kowa Research Institute, Inc. | 96 | 2020-06-10 | 2023-12-22 |
| Efficacy of Fixed-doses of Antihypertensive and Statin Drugs Viena II 160/10, Viena II 190/10, Viena II 160/12 - Hypertension, Dyslipidemia | Phase 2 | Withdrawn | EMS | 2019-01-01 | 2019-10-16 | |
| Capsaicin Effect on Cytokines Profile in Dyslipidemia Capsaicin, Magnesia calcinada - Dyslipidemia, Overweight or Obesity | Phase 2 / Phase 3 | Unknown | University of Guadalajara | 17 | 2016-10-01 | 2016-07-19 |
| Dose-response Study of Carduus Marianus in Centesimal Scale for Dyslipidemia in Climacteric Overweighed or Obese Women. Carduus marianus 6cH, Carduus marianus 12cH, Carduus marianus 30cH - Dyslipidemia, Menopause | Phase 2 | Terminated | Hospital Nacional Homeopático, Mexico | 62 | 2016-02-01 | 2019-02-28 |
| The Effect of a Plant Sterols-Enriched Low-Fat Milk on Lipid Profile in Healthy Southern Chinese (COME-PASS) Plant sterols-enriched low-fat milk, Low-fat milk - Dyslipidemia | Phase 2 | Completed | The University of Hong Kong | 221 | 2015-08-01 | 2015-10-14 |
| Fenofibrate Treatment in SCI Fenofibrate, No intervention - Spinal Cord Injury, Dyslipidemia | Phase 2 / Phase 3 | Completed | VA Office of Research and Development | 23 | 2015-05-18 | 2019-06-26 |
| Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia PRC-4016, Placebo, Statins - Dyslipidemia | Phase 2 | Terminated | Pronova BioPharma | 113 | 2013-11-01 | 2015-10-30 |
| TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP) TA-8995, Atorvastatin, Rosuvastatin - Dyslipidemia | Phase 2 | Completed | Xention Ltd | 364 | 2013-08-01 | 2014-08-21 |
| The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects PRC-4016, Placebo - Dyslipidemia | Phase 2 | Completed | Pronova BioPharma | 87 | 2013-07-01 | 2015-10-30 |
| Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia CAT-2003, Placebo, Statin - Dyslipidemia, Hypercholesterolemia | Phase 2 | Completed | Catabasis Pharmaceuticals | 99 | 2013-07-01 | 2016-07-28 |
| Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia RVX000222, Rosuvastatin, Atorvastatin - Dyslipidemia, Coronary Artery Disease | Phase 2 | Terminated | Resverlogix Corp | 13 | 2013-05-01 | 2015-05-12 |
| Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia Lactobacillus paracasei B21060, low satured diet - Dyslipidemia, Familial Hypercholesterolemia | Phase 1 / Phase 2 | Completed | Federico II University | 40 | 2012-01-01 | 2014-01-29 |
| A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia ZYH7, Fenofibrate - Hypertriglyceridemia, Dyslipidemia | Phase 2 | Completed | Zydus Lifesciences Limited | 109 | 2011-11-01 | 2013-10-28 |
| Effect of Nigella Sativa on Lipid Profiles in Elderly Nigella sative, black sticky rice - Dyslipidemia | Phase 2 | Completed | Universitas Indonesia | 96 | 2011-09-01 | 2012-02-10 |
Showing 20 of 55. Sign in to see all of them.
Dyslipidemias (55) · Hypercholesterolemia (6) · Hypertriglyceridemia (5) · Obesity (5) · Atherosclerosis (4) · Overweight (3) · Coronary Artery Disease (2) · Diabetes Mellitus, Type 2 (2) · Hypertension (2) · Acute Coronary Syndrome (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Epilepsy (1) · HIV Infections (1)
Nutritional and Metabolic Diseases (55) · Lipid Metabolism Disorders (54) · Metabolic Diseases (54) · Hyperlipidemias (10) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Vascular Diseases (6) · Arterial Occlusive Diseases (5) · Arteriosclerosis (5) · Body Weight (5) · Cardiovascular Diseases (5) · Glucose Metabolism Disorders (5) · Nutrition Disorders (5) · Overnutrition (5) · Endocrine System Diseases (4)
Atorvastatin (8) · Fenofibrate (5) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (4) · Rosuvastatin Calcium (3) · Simvastatin (3) · apabetalone (3) · dalcetrapib (3) · 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (2) · Exercise (2) · Niacin (2) · bococizumab (2) · 1-(carboxymethylthio)tetradecane (1) · 1a,3,5,5a-tetrahydro-1H-2,3-diazacyclopropa(a)pentalene-4-carboxylic acid (1) · 3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid (1) · 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopentapyrazole (1)
Akros Pharma Inc. (4) · Merck Sharp & Dohme LLC (4) · Bristol-Myers Squibb (3) · Pfizer (3) · Resverlogix Corp (3) · AstraZeneca (2) · Eli Lilly and Company (2) · Pronova BioPharma (2) · Solvay Pharmaceuticals (2) · Veloxis Pharmaceuticals (2) · Albireo (1) · Catabasis Pharmaceuticals (1) · EMS (1) · Esperion Therapeutics, Inc. (1) · Essentialis, Inc. (1)
United States (29) · Canada (7) · Netherlands (4) · Australia (3) · Denmark (3) · Japan (3) · Sweden (2) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Indonesia (1) · Ireland (1)
Chivers Woodruff, Jr, MD (2) · Cynthia Strout, MD (2) · Dennis McCluskey, MD (2) · Harry Geisberg, MD (2) · James Zavoral, MD (2) · Jeff Geohas, MD (2) · Linda Murray, MD (2) · Mark Kipnes, MD (2) · Michael Noss, MD (2) · Michele Reynolds, MD (2)
PMID 28181260, PMID 29037448, PMID 37994400, PMID 17384435, PMID 19267708, PMID 20110022, PMID 20220185, PMID 20297950, PMID 22089718, PMID 22349989, PMID 23770179, PMID 23958252, PMID 26047975, PMID 26197999, PMID 26564598, PMID 26892135, PMID 27206939, PMID 27678430, PMID 28117400, PMID 36307922, PMID 38504437, PMID 40167413
2005 (2), 2009 (1), 2023 (1), K23DK075360 (1), R21AT003077 (1)